Patient Experiences and Treatment Satisfaction with Mini-Dose Glucagon as a Treatment for Hypoglycemia Following Repeated, Prolonged Fasts in Type 1 Diabetes During Ramadan

<b>Background/Objectives:</b> Mini-dose glucagon (MDG) is a safe and effective option for managing hypoglycemia during prolonged, repetitive fasts in people with type 1 diabetes (pwT1D) during Ramadan. We aimed in this study to evaluate the effectiveness and patient satisfaction of MDG for the management of fasting-induced hypoglycemia from the perspective of pwT1D fasting during Ramadan. <b>Methods:</b> We conducted an online survey shared via social media platforms and email announcements from May 2021 to April 2023 to collect feedback from 136 (72 female) persons with T1D about their experiences using MDG. In the survey, participants were asked to answer questions about diabetes history, hypoglycemia management during Ramadan, the efficacy of MDG treatment, the psychological impact of breaking the fast, side effects, injection experiences, and preferred future treatments for hypoglycemia caused by fasting. <b>Results:</b> After using MDG, 123 (91%) of participants reported they were able to complete their fasts. A total of 110 (80%) of participants reported that they prefer to use MDG over oral options in the future to correct fasting-induced hypoglycemia. Furthermore, participants showed significant change in their habits, which would otherwise have left them exposed to hypoglycemia or hyperglycemia for longer periods of time during fasts. <b>Conclusions:</b> These data demonstrate positive user experience and satisfaction following MDG as a treatment for fasting-induced hypoglycemia in pwT1D. Furthermore, MDG can promote the successful completion of fasts in Ramadan and encourage a change in unhealthy habits that may lead to prolonged hypoglycemia during fasts.